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Abstract: The incidence of pre-eclampsia ranges from 3% to 7% for nulliparas and 1% 
to 3% for multiparas. Pre-eclampsia is a major cause of maternal mortality and   morbidity, 
preterm birth, perinatal death, and intrauterine growth restriction. Unfortunately, the 
pathophysiology of this multisystem disorder, characterized by abnormal vascular response 
to placentation, is still unclear. Despite great polymorphism of the disease, the criteria for 
pre-eclampsia have not changed over the past decade (systolic blood pressure .140 mmHg 
or diastolic blood pressure $90 mmHg and 24-hour proteinuria $0.3 g). Clinical features 
and laboratory abnormalities define and determine the severity of pre-eclampsia. Delivery is 
the only curative treatment for pre-eclampsia. Multidisciplinary management, involving an 
obstetrician, anesthetist, and pediatrician, is carried out with consideration of the maternal 
risks due to continued pregnancy and the fetal risks associated with induced preterm delivery. 
Screening women at high risk and preventing recurrences are key issues in the management 
of pre-eclampsia.
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Introduction
The criteria that define pre-eclampsia have not changed over the past decade.1,2 These 
are: onset at .20 weeks’ gestational age of 24-hour proteinuria $30 mg/day or, if 
not available, a protein concentration $30 mg ($1+ on dipstick) in a minimum of 
two random urine samples collected at least 4–6 hours but no more than 7 days apart, 
a systolic blood pressure .140 mmHg or diastolic blood pressure $90 mmHg as 
measured twice, using an appropriate cuff, 4–6 hours and less than 7 days apart, and 
disappearance of all these abnormalities before the end of the 6th week postpartum. 
Nonetheless, some presentations of pregnancy-related hypertension combined with 
clinical or laboratory abnormalities or intrauterine growth restriction should also be 
considered as potential pre-eclampsia.1
Epidemiology
Pre-eclampsia is a multisystem disorder that complicates 3%–8% of pregnancies 
in Western countries and constitutes a major source of morbidity and mortality 
worldwide.3,4 Overall, 10%–15% of maternal deaths are directly associated with pre-
eclampsia and eclampsia.4 Some epidemiological findings support the hypothesis of a 
genetic and immunological etiology. The risk of pre-eclampsia is 2-fold to 5-fold higher 
in pregnant women with a maternal history of this disorder. Depending on ethnicity, the 
incidence of pre-eclampsia ranges from 3% to 7% in healthy nulliparas and 1% to 3% Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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in multiparas. Moreover, nulliparity and a new partner have 
been shown to be important risk factors (Table 1).5
Other risk factors have been identified, including a 
medical history of chronic hypertension, kidney disease, 
diabetes, obesity, birthplace in Africa, age $35 years, and 
pregnancy characteristics, such as twin or molar pregnancy, 
previous pre-eclampsia, or fetal congenital abnormality.6,7 
High altitude has also been shown to increase the incidence 
of pre-eclampsia, and is attributed to greater placental 
hypoxia, smaller uterine artery diameter, and lower uterine 
artery blood flow.8
Pre-eclampsia may be life-threatening for both mother 
and child, increasing both fetal and maternal morbidity and 
mortality.5 In the mother, pre-eclampsia may cause   premature 
cardiovascular disease, such as chronic   hypertension,   ischemic 
heart disease, and stroke, later in life,9 while children born 
after pre-eclamptic pregnancies and who are   relatively small at 
birth, have an increased risk of stroke, coronary heart disease, 
and metabolic syndrome in adult life.10–12
The sole curative treatment being delivery,   management 
must continuously balance the risk–benefit ratio of induced 
preterm delivery and maternal–fetal complications.   Screening 
women at high risk and preventing recurrences are also key 
issues in the management of pre-eclampsia.
Pathophysiology
During normal pregnancy, the villous cytotrophoblast 
invades into the inner third of the myometrium, and spiral 
arteries lose their endothelium and most of their muscle 
fibers. These structural modifications are associated with 
functional alterations, such that spiral arteries become low-
resistance vessels, and thus less sensitive, or even insensitive, 
to vasoconstrictive substances.
Pre-eclampsia has a complex pathophysiology, the pri-
mary cause being abnormal placentation. Defective invasion 
of the spiral arteries by cytotrophoblast cells is observed 
during pre-eclampsia. Recent studies have shown that 
cytotrophoblast invasion of the uterus is actually a unique 
differentiation pathway in which the fetal cells adopt cer-
tain attributes of the maternal endothelium they normally 
replace. In pre-eclampsia, this differentiation process goes 
awry.13 The abnormalities may be related to the nitric oxide 
pathway, which contributes substantially to the control of 
vascular tone. Moreover, inhibition of maternal synthesis 
of nitric oxide prevents embryo implantation.14 Increased 
uterine arterial resistance induces higher sensitivity to 
vasoconstriction and thus chronic placental ischemia and 
oxidative stress. This chronic placental ischemia causes fetal 
complications, including intrauterine growth retardation 
and intrauterine death. In parallel, oxidative stress induces 
release into the maternal circulation of substances such as 
free radicals, oxidized lipids, cytokines, and serum soluble 
vascular endothelial growth factor 1. These abnormalities 
are responsible for endothelial dysfunction15 with vascular 
hyperpermeability, thrombophilia, and hypertension, so as 
to compensate for the decreased flow in the uterine arteries 
due to peripheral vasoconstriction.
Endothelial dysfunction is responsible for the clinical 
signs observed in the mother, ie, impairment of the hepatic 
endothelium contributing to onset of the HELLP (Hemolysis, 
Elevated Liver enzymes and Low Platelet count) syndrome, 
impairment of the cerebral endothelium inducing refractory 
neurological disorders, or even eclampsia. Depletion of 
  vascular endothelial growth factor in the podocytes makes 
the endotheliosis more able to block the slit diaphragms in the 
basement membrane, adding to decreased glomerular filtra-
tion and causing proteinuria. Finally, endothelial dysfunction 
promotes microangiopathic hemolytic anemia, and vascular 
hyperpermeability associated with low serum albumin causes 
edema, particularly in the lower limbs or lungs.
The crucial issue to understand is that the prime mover 
of pre-eclampsia is abnormal placentation. Two common 
  theories appear to be interlinked, ie, a genetic theory1,16 and an 
immunological theory.17,18 Several susceptibility genes may 
exist for pre-eclampsia.16,19 These genes probably   interact in 
the hemostatic and cardiovascular systems, as well as in the 
inflammatory response. Some have been   identified, and in 
candidate gene studies they have provided   evidence of linkage 
to several genes, including angiotensinogen on 1-q42–43 and 
eNOS on 7q36; other main important loci are 2p12, 2p25, 
9p13, and 10q22.1.16
Pre-eclampsia can be perceived as an impairment of the 
maternal immune system that prevents it from recognizing 
the fetoplacental unit. Excessive production of immune 
cells causes secretion of tumor necrosis factor alpha which 
induces apoptosis of the extravillous cytotrophoblast.17 
The human leukocyte antigen (HLA) system also appears 
to play a role in the defective invasion of the spiral arter-
ies, in that women with pre-eclampsia show reduced levels 
of HLA-G and HLA-E.18 During normal pregnancies, the 
interaction between these cells and the trophoblast is due 
to secretion of vascular endothelial growth factor and pla-
cental growth factor by natural killer cells. High levels of 
soluble fms-like tyrosine kinase 1 (sFlt-1), an antagonist 
of vascular endothelial growth factor and placental growth 
factor, have been found in women with pre-eclampsia.17,18 Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
469
Pre-eclampsia
Accordingly, assays of sFlt-1, placental growth factor, 
endoglin, and   vascular endothelial growth factor, all of 
which increase 4–8 weeks before onset of the disease, may 
be useful predictors of pre-eclampsia. Recent data show the 
protective role of heme oxygenase 1 and its metabolite, car-
bon monoxide, in pregnancy, and identify this as a potential 
target in the   treatment of pre-eclampsia.20
Clinical presentation and  
workup findings
Clinical and laboratory tests are intended to define and 
determine the severity of pre-eclampsia. Headaches, tinnitus, 
phosphene signals, visual disorders, brisk tendon reflexes, 
and vigilance disorders are related to cerebral edema; oliguria 
to acute renal failure; uterine contraction, vaginal bleeding 
to placental abruption; vomiting to HELLP syndrome; band-
like epigastric pain to subcapsular hepatic hematoma; and 
dyspnea to cardiac failure. Eclampsia, the major neurological 
complication of pre-eclampsia, is defined as a convulsive 
episode or any other sign of altered consciousness arising in 
a setting of pre-eclampsia, and which cannot be attributed to 
a pre-existing neurological condition. Clinical examination 
should include resting blood pressure measurement using 
an appropriate cuff, and screening for weight gain, edema 
(including signs of acute pulmonary edema and cerebral 
edema), cardiomyopathy, and acute renal failure. The fetus 
should be assessed by electrocardiotocography. Laboratory 
tests include: a complete blood count with platelets, hapto-
globin, and lactate dehydrogenase; a blood smear to test for 
schistocytes; bilirubin, aspartate transaminase, and alanine 
transaminase in order to identify potential HELPP syndrome; 
electrolyte, urea, and creatinine assessment to check for acute 
renal failure or uremia; 24-hour proteinuria; prothrombin, 
activated thrombin time, and fibrinogen (microangiopathic 
hemolytic anemia); blood group; and irregular antibody 
screening. Other examinations include fetal ultrasound 
with Doppler velocimetry of the umbilical, cerebral, and 
uterine arteries, estimation of fetal weight, assessment of 
fetal well-being by Manning score, and examination of the 
placenta.21
Although the definition of severe pre-eclampsia 
varies,1,21,22 several components of this definition are usually 
accepted: maternal systolic blood pressure $160 mmHg or 
diastolic blood pressure $110 mmHg; maternal neurological 
disorders such as persistent headaches, phosphene signals, 
tinnitus, and brisk, diffuse, polykinetic tendon reflexes, 
eclampsia, acute pulmonary edema, proteinuria $5 g/day, 
oliguria ,500 cc/day, creatinine .120 µmol/L, HELLP 
  syndrome,   thrombocytopenia ,100,000/mm3, and fetal 
criteria, especially intrauterine growth retardation, 
  oligohydramnios, or fetal death in utero. Mild pre-eclampsia 
is defined as diastolic blood pressure $90 mmHg mea-
sured on two occasions at least 6 hours apart, combined 
with proteinuria (two or more occurrences of protein on 
  dipstick, .300 mg total protein in a 24-hour urine collection, 
or a protein   creatinine ratio .30 mg/mmol).1
Immediate emergency 
management
Delivery is the only curative treatment for pre-eclampsia.1 
Management is multidisciplinary, involving an obstetrician, 
an anesthetist, and a pediatrician. In some cases consultation 
of maternal fetal medicine and hypertension or nephrology 
subspecialists may be required. Management decisions must 
balance the maternal risks of continued pregnancy against 
the fetal risks associated with induced preterm delivery.2 
The criteria for delivery are based on two often interrelated 
factors, ie, gestational age at diagnosis (estimated fetal 
weight) and severity of pre-eclampsia.
Severe pre-eclampsia requires treatment with a dual 
aim, ie, preventing the harmful effects of elevated maternal 
blood pressure and preventing eclampsia. Management of 
severe pre-eclampsia begins with transfer of the mother in a 
fully equipped ambulance or helicopter to a maternity ward 
providing an appropriate level of care for both mother and 
child.2 At admission and daily thereafter, clinical, cardiotoco-
graphic, laboratory, and ultrasound testing are required to 
detect the severity of pre-eclampsia and tailor management 
accordingly.22
Regardless of the severity of pre-eclampsia, there is no 
advantage in continuing the pregnancy when pre-eclampsia 
is discovered after 36–37 weeks.23–25 Nor is expectant 
  management justified for severe pre-eclampsia before 
24 weeks, in view of the high risk of maternal complications 
and the poor neonatal prognosis.26–28 The obstetric team must 
then discuss with the parents the possibility of a medical 
  interruption of pregnancy. Prolongation of pregnancy in 
the event of mild pre-eclampsia can be discussed and re-
evaluated on a regular basis. At 34 –37 weeks, management 
depends on the severity of the pre-eclampsia. Expectant man-
agement is possible for mild pre-eclampsia to limit the risk 
of induced preterm delivery, but for severe pre-eclampsia, 
delivery remains the rule due to the increased risk of maternal 
and fetal complications.2,22
Similarly, at 24–34 weeks, management depends on 
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more of the following signs indicates the need for imme-
diate   delivery: uncontrolled severe hypertension (not 
responsive to dual therapy), eclampsia, acute pulmonary 
edema, abruptio   placentae, subcapsular hepatic   hematoma, 
or   thrombocytopenia ,50,000/mm3. Delivery after 
  corticosteroid therapy for pulmonary maturation is necessary 
if any of the following criteria is present: persistent epigastric 
pain, signs of imminent eclampsia (headaches or persistent 
visual disorders), de novo creatinine .120 µmol/L, oliguria 
below 20 mL/hour, progressive HELLP syndrome, prolonged 
or severe variable decelerations with short-term variability 
less than 3 milliseconds. When emergency delivery is not 
required, labor can be induced by cervical ripening.22
Antihypertensive treatment is useful only in severe pre-
  eclampsia because the sole proven benefit of such   management 
is to diminish the risk of maternal   complications (cerebral 
hemorrhage, eclampsia, or acute pulmonary edema).29 There is 
no international consensus concerning antihypertensive treat-
ment in pre-eclampsia. The four drugs authorized for the treat-
ment of hypertension in severe   pre-eclampsia in France are 
nicardipine, labetalol, clonidine, and   dihydralazine.29 There 
is no ideal target blood pressure value, and too   aggressive a 
reduction in blood pressure is harmful to the fetus.30 Therapy 
with a single agent is advised as first-line treatment, followed 
by combination treatment when   appropriate. The algorithm 
for antihypertensive   treatment proposed by French experts22 
is shown in Figure 1.
Pulmonary maturation using corticosteroids must be con-
sidered, taking gestational age into account.   Betamethasone 
remains the gold standard at a dosage of two injections of 
12 mg 24 hours apart; this treatment reduces the risk of 
hyaline membrane disease, intraventricular hemorrhage, and 
neonatal mortality.31
Magnesium sulfate (MgSO4) may be part of the 
  therapeutic armamentarium for severe pre-eclampsia. It 
is indicated in the treatment of eclamptic convulsions as 
well as for secondary prevention of eclampsia, thus replac-
ing treatment by diazepam, phenytoin, or the combination 
of chlorpromazine, promethazine, and pethidine.32 The 
efficacy of MgSO4 in the reduction of maternal and neo-
natal complications of   eclampsia is well established. It is 
administered intravenously, first at a loading dose of 4 g 
over 15–20 minutes, which can be repeated at a half dose 
(2 g) if convulsion recurs, and then at a maintenance dose 
of 1 g/hour for 24 hours.22,32 MgSO4   treatment must be 
monitored in the intensive care unit because organ failure 
may occur. This monitoring is based on repeated check-
ing for a Glasgow score of 15, tendon reflexes, respiratory 
  frequency .12 per minute, and diuresis .30 mL/hour. Any 
manifestation of overdose requires stopping the infusion, 
considering   injection of calcium gluconate, and measuring 
blood magnesium levels.22
Eclampsia is generally considered an indication for 
emergency cesarean section. Nonetheless, a decision to 
delay a cesarean, albeit rare, may be based on fetal status 
and   justified if the mother’s condition is stable and   reassuring 
after treatment.33
Management following delivery
Although delivery is the only effective treatment for 
  pre-eclampsia, and despite the fact that clinical symptoms 
and laboratory abnormalities usually regress in the hours 
  afterwards, the risk of complications persists for some time 
following delivery.6 Pre-eclampsia is associated with long-
term morbidity and mortality. Approximately 20% of women 
with pre-eclampsia develop hypertension or microalbuminu-
ria during long-term follow-up, and the risk of subsequent 
cardiovascular and cerebrovascular disease is doubled in 
women with pre-eclampsia and gestational hypertension 
compared with age-matched controls.34 A recent prospective 
epidemiological study with a median follow-up duration of 
30 years provides evidence that pre-eclampsia is a marker of 
increased mortality from cardiovascular disease.35
Hemodynamic, neurological, and laboratory monitoring 
is necessary following delivery for patients with severe pre-
eclampsia.36 Hemodynamic monitoring includes frequent 
blood pressure measurements to enable adjustment of anti-
hypertensive treatment and frequent monitoring of diuresis 
and weight according to intake (oliguria should prompt 
progressive fluid resuscitation and sometimes diuretic use). 
Neurological monitoring consists of checking for signs of 
imminent eclampsia, including headaches, phosphene sig-
nals, tinnitus, and brisk tendon reflexes. Clinical monitor-
ing must be done several times daily during the week after 
delivery, a period considered at high risk for complications. 
If necessary, monitoring can be performed in an intensive 
care unit.
Laboratory monitoring should be done several times daily 
in the first 72 hours after delivery and thereafter adapted 
according to progress of the indices. It must include a 
  complete blood count, liver function tests, and measurement 
of lactate dehydrogenase. Discharge from hospital cannot 
be considered until all clinical and laboratory indices have 
returned to normal, and regular monitoring by the patient’s 
general practitioner as necessary if treatment for hypertension 
is to be continued after discharge.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The risk of recurrence of pre-eclampsia during a 
  subsequent pregnancy has to be considered. This risk is 
estimated to be less than 10% for all cases of pre-eclampsia,37 
but is greater when pre-eclampsia is discovered before 
28 weeks. The relative risk is 15 if pre-eclampsia occurs at 
20–33 weeks, 10 at 33–36 weeks, and 8 after 37 weeks.37
Three months after delivery, screening for   underlying 
renal or hypertensive disease may be requested by the 
patient’s primary physician. Such screening is intended 
to check for normalization of blood pressure values and 
  disappearance of proteinuria, and if abnormalities persist, 
a referral should be made to a nephrologist or a   hypertension 
expert to determine the cause. This examination is impor-
tant because pre-eclampsia may unmask previously 
  undiagnosed systemic or kidney disease or thrombophilia. 
It should include a specific set of questions, blood pressure 
  measurement, a clinical examination looking for signs of 
autoimmune conditions, and a urinary dipstick test. Testing 
for antiphospholipid antibodies is recommended after severe 
pre-eclampsia. The search for hereditary thrombophilia by 
assays for protein C and S, antithrombin III, and a test for 
resistance to activated protein C is recommended in the case 
SBP > 160 mmHg
SBP > 180 mmHg
or
DBP > 140 mmHg
Initiation of treatment 
Intravenous nicardipine 
0.5–1 mg bolus 
then
30 min of 4 to 7 mg perfusion 
SBP < 180 mmHg
or
DBP < 140 mmHg
Maintenance treatment 
Nicardipine 1–6 mg/h 
or
Intravenous labetalol 5–20 mg/h 
After 30 minutes: Assessment of the therapeutic efficacy and tolerance
140 < SBP < 160 mmHg
100 < DBP < 120 mmHg 
Maintenance treatment
nicardipine 1–6 mg/h 
or
labetalol 5–20 mg/h 
SBP < 140 mmHg
DBP < 100 mmHg 
Reduction or cessation
of the treatment 
 
SBP > 160 mmHg
or
DBP > 120 mmHg
Bitherapy 
Nicardipine 6 mg/h associated to :
Labetalol 5–20 mg/h 
or
Clonidine 15–40 µg/h (if CI to β−)
Side effects
(cephalalgia, palpitations, etc)
Bitherapy 
1.  Reduction of nicardipine and  
2.  Association with: 
Labetalol 5–20 mg/h 
or
Clonidine 15–40 µg/h (if CI to β−)
After 30 minutes and then every hour: reassessment of the therapeutic effect
Figure 1 Algorithm for antihypertensive treatment of pre-eclampsia.22
Note: MBP = [systolic BP + 2 × diastolic BP]/3.
Abbreviations: MBP, mean blood pressure; Ci, contraindication; SBP, systolic blood pressure; DBP, diastolic blood pressure.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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of a personal or family history of venous thromboembolic 
disease, early pre-eclampsia, or pre-eclampsia with any 
intrauterine growth retardation, abruptio placentae, or in utero 
death.22,38 Percutaneous needle biopsy of the kidney should 
be performed only if kidney failure persists at three months 
postpartum or if signs of a systemic underlying condition or 
proteinuria persist at 6 months.23
Patients who have had severe pre-eclampsia may 
share predispositions with nonpregnant patients who 
have   cardiovascular risk factors.39 Accordingly, long-term 
  monitoring of cardiovascular, renal, and metabolic risk 
  factors is recommended after severe pre-eclampsia.22
Prevention
Primary prevention of pre-eclampsia is based on the   detection 
of modifiable risk factors. The literature is plentiful regard-
ing the risk factors for pre-eclampsia, but should be inter-
preted with caution.4–8 Women at high risk are those with a 
personal history of severe pre-eclampsia, while those at low 
risk are defined as those who have never had pre-eclampsia 
but have at least one risk factor.2 There are numerous risk 
factors,4–8 including genetic risk factors, family history of 
  pre-  eclampsia, immunologic factors, nulliparity, a new part-
ner, and demographic factors such as a maternal age .35 
years, the woman’s own gestational age and birth weight (with 
elevated risks for women born before 34 weeks or weighing 
less than 2500 g at birth), factors related to the pregnancy, 
such as multiple pregnancy, congenital or   chromosomal 
anomalies, a hydatidiform mole, or urinary infection, risk 
factors      associated with maternal disease, including chronic 
hypertension, kidney disease, obesity, insulin resistance, 
and diabetes, as well as thrombophilia, and environmental 
factors such as living at a high altitude and stress. Although 
the search for these risk factors is important, they may not 
effectively predict this pre-eclampsia by themselves.
However, accurate prediction of pre-eclampsia would 
enable early and optimal management of women at high risk. 
Several predictive tests are being assessed currently. These 
include clinical tests, such as blood pressure measurement 
during the second trimester or 24-hour ambulatory blood pres-
sure monitoring, but these lack sensitivity and   specificity.40 
Laboratory tests for oxidative response have been assessed, 
including assays for uric acid, urinary kallikrein, and 
fibronectin, but no evidence of their relevance has so far 
been found.40 Among the markers used to screen for tri-
somy 21 during the second trimester (beta human chorionic 
gonadotropin, alpha fetoprotein, and unconjugated estriol), 
elevated alpha fetoprotein is associated with a higher risk of 
pre-  eclampsia (unless there are neural tube abnormalities, 
as when beta human chorionic gonadotropin is elevated). 
Frequent   monitoring of women with elevated levels could 
be useful, but these tests may not be carried out for screening 
purposes due to their low negative predictive value.40 Serum 
markers for trisomy 21 in the first trimester (pregnancy-
  associated plasma protein A, inhibin A, corticotropin-
releasing hormone, and activin) have been tested, but their 
likelihood ratios seem to be insufficient.
Imaging tests have been evaluated, including uterine 
artery Doppler ultrasound.41,42 Uterine artery Doppler ultra-
sound is not advised during the first or second trimester 
in low-risk populations due to the excessive variability 
of likelihood ratios in this population, which allows for 
the prediction of only one-third of pre-eclampsia cases.43 
In a high-risk population, the definition of which is often 
imprecise, uterine artery Doppler can be performed during 
the second trimester morphologic ultrasound examination 
and checked 1 month later in case of abnormal results 
(resistance index .0.58 or 90–95th percentile, unilateral 
or bilateral notch). The combination of a uterine artery 
Doppler examination during the first trimester and a 
three-dimensional ultrasound assessing placental volume 
may predict the risk of pre-eclampsia as early as the first 
trimester.44
In clinical practice, because no single marker effectively 
predicts the risk of pre-eclampsia, the current trend is to 
test a combination of markers. The most commonly used 
  combination of markers assesses sFlt-1, placental growth 
Table 1 Major risk factors for pre-eclampsia49
Risk factor OR or RR (95% CI)
Antiphospholipid antibody  
syndrome
9.7 (4.3–21.7)
Renal disease 7.8 (2.2–28.2)
Prior pre-eclampsia 7.2 (5.8–8.8)
Systemic lupus erythematosus 5.7 (2.0–16.2)
Nulliparity 5.4 (2.8–10.3)
Chronic hypertension 3.8 (3.4–4.3)
Diabetes mellitus 3.6 (2.5–5.0)
High altitude 3.6 (1.1–11.9)
Multiple gestations 3.5 (3.0–4.2)
Strong family history of CV disease  
(heart disease or stroke  
in $2 first-degree relatives)
3.2 (1.4–7.7)
Obesity 2.5 (1.7–3.7)
Family history of pre-eclampsia  
in first-degree relative
2.3–2.6 (1.8–3.6)
Advanced maternal age  
(.40 years)
1.68 (1.23–2.29) for nulliparas 
1.96 (1.34–2.87) for multíparas
Abbreviations: CI, confidence interval; OR, odds ratio; RR, relative risk; CV, 
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  factor, endoglin, and vascular endothelial growth factor 
during the first or second trimester. Increased vascular 
endothelial growth factor and endoglin levels, combined 
with increased sFlt-1 and decreased placental growth factor 
during the first trimester, is associated with a significantly 
increased risk of pre-eclampsia.20
Improved prediction of pre-eclampsia has been noticed 
when serum markers are combined with Doppler indices. In a 
recent nested case-control study, second trimester maternal 
serum cystatin C, C-reactive protein, and uterine artery mean 
resistance index were observed to be independent predictors 
of pre-eclampsia.45
Secondary prevention is based on antiplatelet aspirin 
therapy, which reduces the risk of pre-eclampsia by 10% 
in women who have at least one risk factor.46 No study 
currently allows determination of the exact dosage or the 
best time for initiation of aspirin. However, aspirin should 
be initiated as early as possible, ie, before 12–14 weeks, 
which corresponds to the beginning of the first phase of 
trophoblast invasion. The efficacy of aspirin has been 
shown only in women with previous pre-eclampsia asso-
ciated with intrauterine growth retardation and without 
thrombophilia. Low molecular weight heparin is indicated 
only in cases of complicated thrombophilia (history of 
thromboembolic complications or of pre-eclampsia).47 
Calcium   supplementation at a dosage of 1.5 g/day, begin-
ning at 15 weeks and continued throughout the pregnancy, 
is recommended for prevention of   pre-eclampsia in women 
with a daily calcium intake ,600 mg/day.48 The statins, 
which stimulate HO-1 expression and inhibit sFlt-1 
release, could have the potential to ameliorate early-onset 
pre-  eclampsia.20 Other treatments, such as antioxidant 
  treatment by vitamins C and E,   oligoelements, and nitric 
oxide have no proven efficacy.6
Conclusion
Pre-eclampsia is a rare pregnancy-related disease with an 
unpredictable course that can have serious consequences 
for both the mother and the fetus. The treatment is sim-
ple, ie, delivery. Nonetheless, induced preterm delivery 
requires careful weighing of both maternal and fetal risk–
benefit. Accordingly, identifying delivery criteria in case of 
  pre-eclampsia is crucial to optimal   management. Current 
research focuses on the prediction of onset of pre-eclampsia 
or even severe pre-eclampsia so as to allow early manage-
ment and improve the morbidity and mortality associated 
with this disease. Specific tools for secondary prevention 
must also be developed for   recurrent pre-eclampsia.
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